CD­MOs Nephron and Can­ton each raise hun­dreds of mil­lions in fi­nanc­ing

Nephron Phar­ma­ceu­ti­cals and Can­ton Bi­o­log­ics re­cent­ly an­nounced cap­i­tal rais­es to­tal­ing hun­dreds of mil­lions of dol­lars, join­ing the grow­ing mar­ket for con­tract and de­vel­op­ment man­u­fac­tur­ing com­pa­nies.

South Car­oli­na-based Nephron said Fri­day that it raised $350 mil­lion for “fu­ture growth.” Nephron de­vel­ops and pro­duces gener­ic in­hala­tion so­lu­tions and sus­pen­sion prod­ucts as well as op­er­ates an out­sourc­ing fa­cil­i­ty that makes prod­ucts like pre-filled sy­ringes and IV bags for hos­pi­tals that aim to help mit­i­gate drug short­ages.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA